|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
RGD |
Hyperglycemia after protein ingestion concurrent with injection of a GLP-1 receptor agonist in rats: a possible role for dietary peptides.
|
15879053 |
2005 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
GLP-1 can correct hyperglycemia in diabetic patients, even in those no longer responding to hypoglycemic agents.
|
10415574 |
1999 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
GLP-1 stimulates insulin secretion during hyperglycemia, suppresses glucagon secretion, stimulates (pro)-insulin biosynthesis and decreases the rate of gastric emptying and acid secretion.
|
11124853 |
2000 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are injectable agents used for the treatment of hyperglycemia in type 2 diabetes.
|
28274140 |
2017 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
GLP-1 receptors are involved in the liraglutide-induced relaxation of branched arteries, under normoglycaemic conditions, while GLP-1 inhibition of vascular superoxide levels contributes to GLP-1 receptor-independent potentiation of endothelium-dependent vasodilatation in hyperglycaemia.
|
30403290 |
2019 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
GLP-1 antagonist significantly blocked the inhibitory effect of IES on hyperglycemia from 15 to 120 min (all p < 0.05).
|
30728346 |
2019 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Although glucagon-like peptide 1- (GLP-1-) based therapy of hyperglycemia in burn injury has shown great potential in clinical trials, its safety is seldom evaluated.
|
30800001 |
2019 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
As the reductions in glycated haemoglobin and systolic blood pressure (SBP) in these trials were modest, and both trials lasted only a short period of time, reductions in hyperglycaemia and SBP are unlikely to be involved in the beneficial CV effects of GLP-1 receptor agonists.
|
28431669 |
2017 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Based on our previous finding that GLP-1 could control hyperglycemia by increasing insulin secretion and inhibiting β-cell apoptosis in severe scald injuries, this study further confirmed that Exendin-4 could increase glycemic control following severe scald by preserving the histology of β cells in pancreatic islets and inhibiting their apoptosis.
|
30211851 |
2018 |
|
Hyperglycemia
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Collectively, these results indicated that hyperglycemia decreases GLP-1R expression in RPE cells.
|
25483438 |
2015 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide one (GLP-1)-based therapies for reducing hyperglycemia in type 2 diabetic patients are efficient, though some individuals develop GLP-1 resistance.
|
28683295 |
2017 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide-1 (GLP-1)-based therapy via G protein-coupled receptor (GPCR) GLP-1R, to attenuate hyperglycemia in critical care has attracted great attention.
|
29022064 |
2018 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucagonlike peptide 1 (GLP-1) receptor agonists have been efficacious for the treatment of type 2 diabetes due to their ability to reduce weight and attenuate hyperglycemia.
|
29905825 |
2018 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
In clinical practice, they are also classified as basal or prandial GLP-1 receptor agonists to differentiate between patients who would benefit more from one or another based on characteristics such as previous treatment and the predominance of fasting or postprandial hyperglycemia.
|
28115994 |
2017 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
In contrast, Zac1 expression did not interfere with the signaling of the glucagon-like peptide 1 receptor (GLP-1R), and the GLP-1 analog liraglutide improved hyperglycemia in transplanted experimental diabetic mice.
|
22547676 |
2012 |
|
Hyperglycemia
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In this study, fecal microbiota transplantation (FMT) using fecal material from metformin-treated mice was found to upregulate the expression of GLP-1 and pattern-recognition receptors TLR1 and TLR4 for the improvement in hyperglycemia caused by a high-fat diet.
|
31501716 |
2019 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
In view of the predisposition of patients with chronic hyperglycaemia to glucagon-like peptide 1 receptor (GLP-1R) downregulation and the lag time to optimal efficacy of GLP-1R agonists, we propose that patients should have C-peptide levels measured to determine the risk of ketosis and whether insulin should be continued with dose adjustments when starting a GLP-1R agonist.
|
28710307 |
2017 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Incretin hormones (glucagon-like peptide-1 [GLP-1] and gastric inhibitory polypeptide [GIP]) may play a role in the development of glucose intolerance and hyperglycemia in patients with hyperthyroidism.
|
28452237 |
2017 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Moreover, ursolic acid is more effective than betulinic acid in reduction of hyperglycemia and increase of GLP-1 secretion.
|
28756460 |
2017 |
|
Hyperglycemia
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Nevertheless, chronic treatment of diabetic mice with P5 increased adipogenesis, reduced adipose tissue inflammation as well as hepatic steatosis and was more effective at correcting hyperglycaemia and lowering haemoglobin A1c levels than Exendin-4, suggesting that GLP-1R G-protein-biased agonists may provide a novel therapeutic approach to T2DM.
|
26621478 |
2015 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our results identify D-allulose as prominent GLP-1 releaser that acts via vagal afferents to restrict feeding and hyperglycemia.
|
29317623 |
2018 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Pasireotide-induced hyperglycemia occurs early, within the first 3 months of treatment, due to a decrease in insulin secretion secondary to a fall in secretion of GLP-1 and GIP, and potentially also due to a direct inhibitory effect of pasireotide on beta cells.
|
28579289 |
2017 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Single-cell digital PCR revealed GLP-1 receptor expression in neurogliaform cells and showed that copy numbers of mRNA of the Glp1r gene in hyperglycaemia exceeded those in hypoglycaemia by 9.6 times (p < 0.008).
|
30637442 |
2019 |
|
Hyperglycemia
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Sitagliptin, a dipeptidyl peptidase-IV inhibitor (DPP-4), sustains activity of the incretin hormones GLP-1 and GIP and improves hyperglycemia in Type 2 diabetes mellitus (T2DM).
|
29138226 |
2018 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
The implications of these findings are very important for the management of type 2 diabetes given that GLP-1 receptor agonist are currently approved for the treatment of hyperglycemia and glucagon receptor antagonists and GLP-1/glucagon dual agonists are under development.
|
28463898 |
2017 |